Design and analysis of Phase III trials with ordered outcome scales: The concept of the sliding dichotomy

被引:120
作者
Murray, GD
Barer, D
Choi, S
Fernandes, H
Gregson, B
Lees, KR
Maas, AIR
Marmarou, A
Mendelow, AD
Steyerberg, EW
Taylor, GS
Teasdale, GM
Weir, CJ
机构
[1] Univ Edinburgh, Sch Med, Edinburgh EH8 9AG, Midlothian, Scotland
[2] Queen Elizabeth Hosp, Stroke Team, Gateshead, England
[3] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA USA
[4] Addenbrookes Hosp, Cambridge, England
[5] Newcastle Gen Hosp, Dept Neurosurg, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England
[6] Univ Glasgow, Western Infirm, Gardiner Inst, Glasgow G11 6NT, Lanark, Scotland
[7] Erasmus Univ, MC Rotterdam, Dept Neurosurg, Rotterdam, Netherlands
[8] Virginia Commonwealth Univ, Div Neurosurg, Richmond, VA USA
[9] Erasmus Univ, MC Rotterdam, Dept Publ Hlth, Rotterdam, Netherlands
[10] Royal Coll Phys & Surgeons Glasgow, Glasgow, Lanark, Scotland
[11] Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8QQ, Lanark, Scotland
关键词
Glasgow outcome scale; neuroprotection; ordered outcome scales; rankin scale; sliding dichotomy;
D O I
10.1089/neu.2005.22.511
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
The conventional approach to the analysis of a Phase III trial in head injury or stroke takes an ordered scale measuring functional outcome and collapses the scale to a binary outcome of favorable versus unfavorable. This discards potentially relevant information which limits statistical power and moreover is not in accord with clinical practice. We propose an alternative approach where a favorable outcome is defined as better than would be expected, taking account of each individual patient's baseline prognosis. This is illustrated through a worked example based on data from a Phase III trial in head injury. The approach is also compared with the proportional odds model, which is another statistical approach that can exploit an ordered outcome scale. The approach raises issues of clinical, statistical, and regulatory importance, and we initiate what we believe needs to become a widespread debate amongst the community involved in clinical research in head injury and stroke.
引用
收藏
页码:511 / 517
页数:7
相关论文
共 21 条
[1]   Measuring outcomes as a function of baseline severity of ischemic stroke [J].
Adams, HP ;
Leclerc, JR ;
Bluhmki, E ;
Clarke, W ;
Hansen, MD ;
Hacke, W .
CEREBROVASCULAR DISEASES, 2004, 18 (02) :124-129
[2]  
BARER D, 1998, CEREBROVASC DIS, V8, P47
[3]   Could stroke trials be missing important treatment effects? [J].
Berge, E ;
Barer, D .
CEREBROVASCULAR DISEASES, 2002, 13 (01) :73-75
[4]  
Bolland K, 1998, STAT MED, V17, P2835, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2835::AID-SIM933>3.3.CO
[5]  
2-#
[6]   RECOVERY OF MOTOR FUNCTION AFTER STROKE [J].
BONITA, R ;
BEAGLEHOLE, R .
STROKE, 1988, 19 (12) :1497-1500
[7]  
*COMM PROP MED PRO, 2001, CPMPEWP56098
[8]  
Edwards D, 1999, STAT MED, V18, P771, DOI 10.1002/(SICI)1097-0258(19990415)18:7<771::AID-SIM80>3.0.CO
[9]  
2-E
[10]   Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) [J].
Hacke, W ;
Kaste, M ;
Fieschi, C ;
von Kummer, R ;
Davalos, A ;
Meier, D ;
Larrue, V ;
Bluhmki, E ;
Davis, S ;
Donnan, G ;
Schneider, D ;
Diez-Tejedor, E ;
Trouillas, P .
LANCET, 1998, 352 (9136) :1245-1251